Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07198477

Sleep Disturbances and Their Association With Serum Magnesium Level in Patients With Major Depressive Disorder

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
90 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This cross-sectional study investigates the relationship between serum magnesium levels and the presence of sleep disturbances among patients with major depressive disorder (MDD).

Detailed description

Major depressive disorder is a highly prevalent psychiatric condition often accompanied by disabling sleep disturbances, including insomnia and hypersomnia. Evidence suggests that magnesium, a vital trace element involved in neurotransmission, stress response, and circadian regulation, may play a crucial role in both mood and sleep. Low serum magnesium levels have been linked to increased depressive symptom severity and disturbed sleep quality. This study seeks to explore whether hypomagnesemia can serve as a biological contributor to sleep dysfunction in MDD. By employing the Beck Depression Inventory-II (BDI-II) and the Pittsburgh Sleep Quality Index (PSQI), as well as laboratory measurement of serum magnesium levels, the study aims to determine whether lower magnesium is significantly associated with greater depressive burden and poor sleep outcomes. The findings may help validate magnesium as a biomarker for early screening and risk stratification in psychiatric care.

Conditions

Timeline

Start date
2026-08-30
Primary completion
2027-10-30
Completion
2027-12-30
First posted
2025-09-30
Last updated
2025-09-30

Source: ClinicalTrials.gov record NCT07198477. Inclusion in this directory is not an endorsement.

Sleep Disturbances and Their Association With Serum Magnesium Level in Patients With Major Depressive Disorder (NCT07198477) · Clinical Trials Directory